Marc TessierLavigne - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

  Director
Dr. Marc TessierLavigne, Ph.D., is Independent Director of the Company. He was the President of Stanford University since September 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from March 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. TessierLavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. TessierLavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc.
Age: 58  Director Since 2011  Ph.D    
914 847-7000  www.regeneron.com
TessierLavigne distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led the board to conclude that Dr. TessierLavigne should serve as a director.

Marc TessierLavigne Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.23 % which means that it generated profit of $0.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.32 % meaning that it created $0.32 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert ScullyZoetis
2013
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Herman MorrisPerrigo Company Plc
1999
James KangOrigin Agritech Limited
2010
David GreenwayVertex Pharmaceuticals Incorpor
2017
Gregory NordenZoetis
2013
Shlomo YanaiPerrigo Company Plc
N/A
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Theodore SamuelstoPerrigo Company Plc
2017
Geoffrey ParkerPerrigo Company Plc
2016
Fei WangOrigin Agritech Limited
2019
Ellen HoffingPerrigo Company Plc
2008
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Bharat DoshiDr Reddys Laboratories Ltd
2016
Willie ReedZoetis
2014
Jacqualyn FousePerrigo Company Plc
2012
Alan GarberVertex Pharmaceuticals Incorpor
2017
J MoreauDr Reddys Laboratories Ltd
2007
Min TangOrigin Agritech Limited
2009
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Louise ParentZoetis
2013

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

ABBV   
Purchased over 40 shares of
a day ago
Traded for 83.54
BDX   
Purchased a lot of shares of
a day ago
Traded for 278.25
UBER   
Purchased over 90 shares of
a day ago
Traded for 36.8
FB   
Purchased over 30 shares of
a day ago
Traded for 217.94
BTI   
Purchased over 90 shares of
a day ago
Traded for 44.55
Additionally take a look at Your Equity Center. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.